EMA Authorised: Avzivi (bevacizumab) — FGK Representative Service GmbH

View source ↗

Summary

EMA authorised Avzivi (bevacizumab) for multiple indications including colorectal cancer, non-small cell lung cancer, renal cell carcinoma, ovarian cancer, fall…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Colorectal Cancer
• Fallopian Tube Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Peritoneal Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Avzivi (bevacizumab)

Snippet

Status: Authorised. Therapeutic area: Colorectal Neoplasms;Carcinoma, Non-Small-Cell Lung;Carcinoma, Renal Cell;Ovarian Neoplasms;Fallopian Tube Neoplasms;Peritoneal Neoplasms;Uterine Cervical Neoplasms. MAH: FGK Representative Service GmbH. Decision date: 27/01/2026